ROHTO Pharmaceutical Co., Ltd. And Dynamics Therapeutics Enter Into Licensing Agreement For Anti-aging Ingredient Supplamine

Tokyo, June 8, 2006 (JCN) - Rohto Pharmaceutical announced on June 7 that it has concluded a licensing agreement with US venture company Dynamics Therapeutics. Under the agreement terms, Rohto will exclusively be able to use Supplamine, an anti-aging ingredient developed by Dynamics Therapeutics, and the related technologies.

Back to news